Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Krassnoff, Jerome Rotter


Bacterial typing systems developer PathoGenetix has hired Paul Krassnoff to be director of manufacturing. In this post, he will develop production and quality assurance systems for the firm's Genome Sequence Scanning System.

Krassnoff formerly was director of lab operations and manufacturing at Aushon Biosystems. He also worked at Alpo Diagnostics, Genzyme Diagnostics, BioMérieux, and Baxter-Dade. He holds a BS in chemistry from Boston University and an MS in biomedical science from Northeastern University.

Jerome Rotter has joined the faculty of the Los Angeles Biomedical Research Institute to launch the Translational Genomics and Population Sciences institute, which aims to use genomics to improve the health of the Hispanic, African-American, and Asian populations served by LA BioMed and the Harbor University of California, Los Angeles Medical Center.

Rotter was previously director of research at the Medical Genetics Institute at Cedars-Sinai Medical Center. He is also a professor of medicine, pediatrics, and human genetics at UCLA and Cedars-Sinai and he has held the board of governors' chair in medical genetics at Cedars-Sinai. He holds a BS and MD from UCLA.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.